School of Medicine, MD/PhD Program, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Mail Code: L357, Portland, OR, 97239, USA.
School of Public Health, Oregon Health & Science University-Portland State University, Portland, OR, USA.
J Gen Intern Med. 2020 Aug;35(8):2365-2374. doi: 10.1007/s11606-020-05815-0. Epub 2020 Apr 14.
Hospitalization of patients with opioid use disorder (OUD) is increasing, yet little is known about opioid agonist therapy (OAT: methadone and buprenorphine) administration during admission.
Describe and examine patient- and hospital-level characteristics associated with OAT receipt during hospitalization in the Veterans Health Administration (VHA).
A total of 12,407 unique patients, ≥ 18 years old, with an OUD-related ICD-10 diagnosis within 12 months prior to or during index hospitalization in fiscal year 2017 from 109 VHA hospitals in the continental U.S.
OAT received during hospitalization.
Few admissions received OAT (n = 1914; 15%) and when provided it was most often for withdrawal management (n = 834; 7%). Among patients not on OAT prior to admission who survived hospitalization (n = 10,969), 2.0% (n = 203) were newly initiated on OAT with linkage to care after hospital discharge. Hospitals varied in the frequency of OAT delivery (range, 0 to 43% of qualified admissions). Patients with pre-admission OAT (adjusted odds ratio [AOR] = 15.30; 95% CI [13.2, 17.7]), acute OUD diagnosis (AOR = 2.3; 95% CI [1.99, 2.66]), and male gender (AOR 1.52; 95% CI [1.16, 2.01]) had increased odds of OAT receipt. Patients who received non-OAT opioids (AOR 0.53; 95% CI [0.46, 0.61]) or surgical procedures (AOR 0.75; 95% CI [0.57, 0.99]) had decreased odds of OAT receipt. Large-sized (AOR = 2.0; 95% CI [1.39, 3.00]) and medium-sized (AOR = 1.9; 95% CI [1.33, 2.70]) hospitals were more likely to provide OAT.
In a sample of VHA inpatient medical admissions, OAT delivery was infrequent, varied across the health system, and was associated with specific patient and hospital characteristics. Policy and educational interventions should promote hospital-based OAT delivery.
因阿片类药物使用障碍(OUD)而住院的患者人数不断增加,但人们对在退伍军人事务部(VHA)住院期间接受阿片类激动剂治疗(OAT:美沙酮和丁丙诺啡)的情况知之甚少。
描述并检查与 2017 财年期间美国大陆 109 家 VHA 医院 12 个月内或期间因 OUD 相关 ICD-10 诊断而住院的患者和医院特征相关的 OAT 接受情况。
共 12407 名年龄≥18 岁的独特患者,在 2017 财年期间因 OUD 相关 ICD-10 诊断而住院,或在住院前 12 个月内有 OUD 相关 ICD-10 诊断。
住院期间接受的 OAT。
很少有入院患者接受 OAT(n=1914;15%),而提供的 OAT 最常用于戒断管理(n=834;7%)。在未入院前接受 OAT 治疗且存活出院的患者(n=10969)中,有 2.0%(n=203)在出院后新开始接受 OAT 治疗并与治疗机构建立联系。各医院提供 OAT 的频率存在差异(范围为 0 至 43%的合格入院患者)。入院前接受 OAT 治疗(调整后的优势比 [AOR],15.30;95%CI [13.2,17.7])、急性 OUD 诊断(AOR,2.3;95%CI [1.99,2.66])和男性(AOR 1.52;95%CI [1.16,2.01])的患者更有可能接受 OAT 治疗。接受非 OAT 类阿片类药物(AOR,0.53;95%CI [0.46,0.61])或手术治疗(AOR,0.75;95%CI [0.57,0.99])的患者接受 OAT 的可能性较低。大型(AOR=2.0;95%CI [1.39,3.00])和中型(AOR=1.9;95%CI [1.33,2.70])医院更有可能提供 OAT。
在 VHA 住院内科入院患者中,OAT 的使用并不常见,在整个医疗体系中存在差异,且与特定的患者和医院特征相关。政策和教育干预措施应促进医院提供 OAT。